glp 1 drugs and ms Glucagon-like peptide-1 agonist safety efficacy in a multiple sclerosis cohort New research is testing Targeted_Treatments Quantity:30 CT (1 Bottle)

glp 1 drugs and ms Glucagon-like peptide-1 agonist safety efficacy in a multiple sclerosis cohort New research is testing Targeted_Treatments Quantity:30 CT (1 Bottle)

New research is testing whether GLP-1 medications (the same ones used for diabetes and weight loss) can help reduce alcohol use. Early trials show they can lower heavy drinking days and cravings.

For a comprehensive review of the anti-obesity effects of GLP-1RAs, which is beyond the purpose of this article, see ref

Targeted_Treatments

Quantity:30 CT (1 Bottle)

Somatostatin inhibits glucagon secretion via paracrine mechanisms and, when blocked, stimulates glucagon release in isolated rat islets [585,586]